Press Release: Addex Therapeutics Establishes Scientific Advisory Board

World-leading experts will support our strategic decision-making

processes as we continue advancing our pipeline of allosteric modulators

Geneva, Switzerland, May 19, 2020 - Addex Therapeutics Ltd (SIX and

Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering

allosteric modulation-based drug discovery and development, announced

today that it has established a Scientific Advisory Board (SAB) led by

Darryle Schoepp, PhD, as Chairman (see

https://www.globenewswire.com/Tracker?data=TLTOvVzW9-WIrgXNIY1Y3jHk_Tj3re9ov8BeGqvOjEcUC2i4OaaJJUFdBw3QlWC50YgHY4uaZsgytXvWwmaCJocx121U84SVo5i8PHD27kt5lwPU_G3w_ep6q7Ua6FW5KfqM1jw_4Jrws9BnKoZhSecKttUc4AwCxYW6bwGDdGetw2o1oN5BYjZexM74y0icdVb2T0JNt-9FjZ92t3wvsKLHy89syv2zSK7iec9sHiYt-8ys2gcY8Ro3veSp-gpmCZ1a9WihJ53J_q599cnAT-BIsEGB9fqti3ev52qDp1lTXKqVosfpnmxsu37qT6In

Press Release) and including fellow world-leading neuroscientists and

drug discovery & development experts, Prof. Mark F. Bear, PhD, Peter R.

Bernstein, PhD, and Prof. Bernard Bettler, PhD. The SAB will provide

valuable insight to help steer future application of Addex proprietary

allosteric modulation technology platform and unique pipeline in

neurological and other diseases.

"The formation of our SAB with these world-leading experts is an

important step for us as we not only execute on our registration program

with dipraglurant in PD-LID, but look to our preclinical pipeline as it

progresses towards the clinic," said Tim Dyer, Chief Executive Officer

of Addex. "Their expertise will be invaluable as we execute on our

strategy to build a leading neuroscience company based on allosteric

modulation."

Dr. Mark Bear is a Picower Professor of Neuroscience in The Picower

Institute for Learning and Memory and the Department of Brain and

Cognitive Sciences, Massachusetts Institute of Technology. He was an

Investigator of the Howard Hughes Medical Institute for 22 years. Dr.

Bear's laboratory has substantially advanced knowledge of how cerebral

cortex is modified by experience. He made fundamental discoveries on

bidirectional synaptic plasticity, metaplasticity, the molecular basis

of amblyopia (a cause of visual disability in children), and the

pathophysiology of fragile X syndrome (the most common inherited cause

of intellectual disability and autism). He has been at the forefront of

the efforts to translate knowledge of autism pathophysiology into new

treatments.

During his distinguished career at AstraZeneca, Dr. Peter Bernstein

helped develop multiple treatments, acting via different mechansims of

action, targeting several diseases. More than 10 of these compounds

entered into clinical development. Early in his career he co-invented

and helped develop Accolate(R) (Zafirlukast), the first leukotriene

antagonist to be approved in the US. Dr. Bernstein then went on to work

on or lead teams targeting: neurokinin antagonists, -estrogen

agonists, -secretase inhibitors, H3 antagonists, 5-HT(1B)

antagonists and dual NET/DAT reuptake inhibitors. Dr. Bernstein is an

author on over 200 scientific papers, presentations, and patents. He is

a member of the ACS MEDI Hall of Fame and is a fellow of the American

Chemical Society.

Dr. Bernard Bettler is a Professor in the Department of Biomedicine at

Basel University, Switzerland. His laboratory is exploring GPCR

complexes and how the composition of these complexes influences

fundamental processes, such as neuronal excitability and network

activity, with the ultimate goal of identifying novel drug targets for

the treatment of neurological and psychiatric diseases. He was

previously a project manager at Novartis working on GABA(B) receptors, a

receptor he cloned and helped characterise. While at Novartis his team

identified the first allosteric modulators at GABA(B) receptors. Dr.

Bettler is the 2017 recipient of the Peter Speiser Award from the ETH

Zurich for outstanding achievments in the pharmaceutical sciences.

About Addex Therapeutics

https://www.globenewswire.com/Tracker?data=3jOzMmrb_myWpmJV5Q9V4es7GwqsZ9qz1OcvsjF0s9XicTX23DI4pb7D1ShmPb0xyfrPli8bHSKI-VmBweLtzNpjS8bo_dJ68yxn-MMScu8=

Addex Therapeutics is a clinical-stage pharmaceutical company focused on

the development and commercialization of an emerging class of novel

orally available small molecule drugs known as allosteric modulators for

neurological disorders. Allosteric modulators offer several potential

advantages over conventional non-allosteric molecules and may offer an

improved therapeutic approach to conventional "orthosteric" small

molecule or biological drugs. Addex's allosteric modulator drug

discovery platform targets receptors and other proteins that are

recognized as essential for therapeutic intervention. Addex's lead drug

candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is

scheduled to enter a pivotal registration clinical trial for Parkinson's

disease levodopa induced dyskinesia (PD-LID). In parallel,

dipraglurant's therapeutic use in dystonia is being investigated in

preclinical models. Addex's second clinical program, ADX71149 (mGlu2

positive allosteric modulator or PAM) is being developed in

collaboration with Janssen Pharmaceuticals, Inc for the treatment of

epilepsy. In addition, Addex's GABA(B) PAM program has been licensed to

Indivior PLC for the treatment of addiction. Preclinical programs

include GABA(B) PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild

neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3

PAM for neurodegenerative disorders.

Press Contacts:

Tim Dyer Mike Sinclair

Chief Executive Officer Partner, Halsin Partners

Telephone: +41 22 884 15 55 +44 (0)20 7318 2955

Email: mailto:PR@addextherapeutics.com PR@addextherapeutics.com mailto:msinclair@halsin.com msinclair@halsin.com

---------------------------------------------------------------- -------------------------------------------------

Forward Looking Statements

Certain statements made in this announcement are forward-looking

statements including with respect to the creation of a trading market

for ADSs representing the Company's shares in the United States. These

forward-looking statements are not historical facts but rather are based

on the Company's current expectations, estimates, and projections about

its industry; its beliefs; and assumptions. Words such as 'anticipates,'

'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and

similar expressions are intended to identify forward-looking statements.

These statements are not guarantees of future performance and are

subject to known and unknown risks, uncertainties, and other factors,

some of which are beyond the Company's control, are difficult to predict,

and could cause actual results to differ materially from those expressed

or forecasted in the forward-looking statements. The Company cautions

securityholders and prospective securityholders not to place undue

reliance on these forward-looking statements, which reflect the view of

the Company only as of the date of this announcement. The

forward-looking statements made in this announcement relate only to

events as of the date on which the statements are made. The Company will

not undertake any obligation to release publicly any revisions or

updates to these forward-looking statements to reflect events,

circumstances, or unanticipated events occurring after the date of this

announcement except as required by law or by any appropriate regulatory

authority.

(END) Dow Jones Newswires

May 19, 2020 01:00 ET (05:00 GMT)